Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan
| Autor: | Katherine Tayler-Smith, Safieh Shah, Mubarak Alnour, Rony Zachariah, Johan van Griensven, François Chappuis, Ann Mumina, Philippa Boulle, Atia M. Atia, Mousab Siddig Elhag, Gabriel Alcoba |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Paromomycin Sodium stibogluconate Treatment outcome Antiprotozoal Agents Treatment failure Sudan Recurrence Prevalence medicine Humans Treatment Failure Child Protozoal disease Retrospective Studies Gynecology Phlebotomus argentipes business.industry Patient Selection Malnutrition Public Health Environmental and Occupational Health Infant Anemia medicine.disease Surgery Infectious Diseases Visceral leishmaniasis Antimony Sodium Gluconate Child Preschool Leishmaniasis Visceral Drug Therapy Combination Female Lost to Follow-Up Parasitology business medicine.drug |
| Zdroj: | Tropical Medicine & International Health. 20:1674-1684 |
| ISSN: | 1365-3156 1360-2276 |
| DOI: | 10.1111/tmi.12603 |
| Popis: | Objectives Among patients with primary and relapse visceral leishmaniasis (VL) in eastern Sudan, we determined the proportion eligible for treatment with sodium stibogluconate and paromomycin (SSG/PM) and, of these, their demographic and clinical characteristics; initial treatment outcomes including adverse side effects requiring treatment discontinuation; treatment outcomes by 6 months; and risk factors associated with initial (slow responders) and late treatment failure (relapses and post-kala-azar dermal leishmaniasis, PKDL). Methods A retrospective cohort study in Tabarak Allah Hospital, Gedaref Province, eastern Sudan, from July 2011 to January 2014. Results Of 1252 individuals diagnosed with VL (1151 primary and 101 relapses), 65% were eligible for SSG/PM including 83% children, almost half of them malnourished and anaemic. About 4% of individuals discontinued treatment due to side effects; 0.7% died during treatment. Initial cure was achieved in 93% of 774 primary cases and 77% of 35 relapse cases (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text